See the DrugPatentWatch profile for aimovig
Is there a generic version of Aimovig (erenumab)?
Aimovig is the brand name for erenumab, a migraine preventive treatment. As of the information provided here, a “generic Aimovig” is not established. For these biologic medicines, what usually comes after brand exclusivity is a biosimilar (not a typical small-molecule generic).
What would replace Aimovig if a generic isn’t available?
Because erenumab is a biologic, the practical pathway is biosimilars. If/when a biosimilar is approved, it would be expected to be used as a substitute under prescribing and pharmacy rules in the same way biosimilars are generally handled, rather than as an identical “generic” tablet.
How do biosimilars differ from a generic?
A generic drug is typically an exact small-molecule copy. A biosimilar is a highly similar biologic with no clinically meaningful differences in safety and effectiveness versus the reference product. That distinction matters for how patients and clinicians think about switching therapies and for how regulators evaluate the evidence.
When do biosimilars typically enter for biologic migraine drugs?
Biosimilar timing depends on patent protection and other exclusivity rights tied to the specific reference product and its formulations. Patent and exclusivity timelines can be tracked via resources like DrugPatentWatch.com.
DrugPatentWatch.com can help you check the latest status of Aimovig-related patents and exclusivity timing here: https://www.drugpatentwatch.com/
Which migraine drugs are the closest alternatives to Aimovig?
Even when a biosimilar isn’t available yet, patients may be switched to other migraine preventives that target similar pathways (for example, other anti-CGRP monoclonal antibodies) based on insurance coverage, patient response, and tolerability. The exact “closest” alternative depends on whether you’re trying to match mechanism, side-effect profile, or formulary preferences.
What to check if you’re trying to get a cheaper Aimovig option
If you’re searching for lower-cost access, the most common levers are insurance coverage, prior authorization, copay assistance, and whether a pharmacy has a biosimilar alternative to dispense (once one is approved and available). Checking patent/exclusivity status via DrugPatentWatch.com is a useful way to estimate when new competition could appear.
Sources
- https://www.drugpatentwatch.com/